Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies
- 1 December 2005
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 2 (S1) , S30-S35
- https://doi.org/10.1038/ncponc0346
Abstract
Nature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.Keywords
This publication has 16 references indexed in Scilit:
- Results of a phase I/II study of the combination of 5-aza-2’-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndromeJournal of Clinical Oncology, 2005
- Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs supportive care (SC) in patients with advanced myelodysplastic syndromes (MDS)Journal of Clinical Oncology, 2005
- Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.Blood, 2004
- New Paradigm in the Management of Myelodysplastic SyndromesCancer Control, 2004
- New agents in acute myeloid leukemia and other myeloid disordersCancer, 2004
- Myelodysplastic SyndromesHematology-American Society Hematology Education Program, 2004
- Gene Silencing in Cancer in Association with Promoter HypermethylationNew England Journal of Medicine, 2003
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- Induction of Differentiation and Apoptosis— A Possible Strategy in the Treatment of Adult Acute Myelogenous LeukemiaThe Oncologist, 2000
- Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly PatientsJournal of Clinical Oncology, 2000